

1 **SLC25A48 is a human mitochondrial choline transporter**

2

3 Suraj Patil ^{1,6,9}, Oleg Borisov ², Nora Scherer ^{2,6}, Christophe Wirth ³, Pascal Schlosser ²,
4 Matthias Wuttke ², Kai-Uwe Eckardt ^{4,5}, Carola Hunte ^{3,7,8}, Björn Neubauer ¹, Anna Köttgen ^{2,7},
5 Michael Köttgen ^{1,7}

6

7

8 **Affiliations:**

9

10 ¹ Department of Medicine IV - Nephrology and Primary Care, Faculty of Medicine and Medical
11 Center, University of Freiburg, Freiburg, Germany

12

13 ² Institute of Genetic Epidemiology, Faculty of Medicine and Medical Center—University of Freiburg,
14 Freiburg, Germany

15

16 ³ Institute of Biochemistry and Molecular Biology, ZBMZ, Faculty of Medicine, University of Freiburg,
17 Freiburg, Germany.

18

19 ⁴ Department of Nephrology and Medical Intensive Care, Charité—Universitätsmedizin Berlin,
20 Germany

21

22 ⁵ Department of Nephrology and Hypertension, University Hospital Erlangen, Friedrich-Alexander-
23 Universität Erlangen-Nürnberg, Erlangen, Germany

24

25 ⁶ Spemann Graduate School of Biology and Medicine (SGBM), University of Freiburg, Freiburg,
26 Germany

27

28 ⁷ CIBSS - Centre for Integrative Biological Signalling Studies, University of Freiburg, Freiburg, Germany

29

30 ⁸ BIOS-Centre for Biological Signalling Studies, University of Freiburg, Freiburg, Germany.

31

32 ⁹ Faculty of Biology, University of Freiburg, Germany

33

34 **Correspondence:**

35

36 Anna Köttgen, MD MPH
37 Institute of Genetic Epidemiology
38 Medical Center – University of Freiburg
39 Hugstetter Str. 49, 79106 Freiburg, Germany
40 anna.koettgen@uniklinik-freiburg.de

41

42 Michael Köttgen, MD
43 Department of Medicine IV - Nephrology and Primary Care
44 Medical Center – University of Freiburg
45 Institute for Disease Modeling and Targeted Medicine
46 Breisacherstr. 113, 79106 Freiburg, Germany
47 michael.koettgen@uniklinik-freiburg.de

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

48 **Abstract**

49 Choline has important physiological functions as a precursor for essential cell components and
50 signaling molecules including phospholipids and the neurotransmitter acetylcholine. Choline
51 is a water-soluble charged molecule and therefore requires transport proteins to cross
52 biological membranes. Membrane transport of choline is incompletely understood. Here we
53 show that SLC25A48 is a human mitochondrial choline transporter. Loss-of-function mutations
54 in *SLC25A48* are associated with elevated urine and plasma choline levels resulting from
55 impaired choline transport into mitochondria.

56 **Main**

57 Membrane transport proteins play a crucial role in the movement of ions and metabolites
58 across biological membranes. Their proper functioning is essential for many physiological
59 processes. Despite significant progress in our understanding of these proteins, a substantial
60 number of them remain uncharacterized, often referred to as orphan membrane transport
61 proteins¹. Deorphanization efforts are essential to unveil the hidden cellular functions and
62 roles of these proteins in health and disease. Recent large-scale genome-wide association
63 studies of metabolite levels (mGWAS) provide links between common genetic variants in
64 membrane transporter-encoding genes and metabolite levels^{2,3}. This generates testable
65 hypotheses to identify the physiological substrates of established and orphan human
66 transport proteins *in vivo*.

67

68 Choline is an essential nutrient with important roles in a variety of physiological processes and
69 metabolic pathways. It is an essential component of phospholipids in cell membranes such as
70 phosphatidylcholines, a precursor of the neurotransmitter acetylcholine and of the
71 osmoregulatory betaine, and an important player in lipid metabolism⁴. Recent studies have
72 uncovered a growing body of evidence linking choline to various diseases such as neurological
73 disorders, metabolic syndromes, and liver disease⁴. Several choline transport proteins have
74 been identified and characterized in model systems, including SLC5A7, SLC44A1, SLC44A2,
75 SLC44A4, FLVCR1, and FLVCR2⁵⁻¹⁰. However, it is unclear which transporters affect systemic
76 levels of free choline in humans and if they are linked to human genetic variation.

77

78 We previously found through mGWAS that common *SLC25A48* variants associate with altered
79 choline levels in urine (**Fig. 1a**)², and now established that the genetic basis of this association

80 is shared with plasma choline as well as *SLC25A48* transcript levels in brain tissue
81 (**Supplementary Fig. 1**), supporting the hypothesis that the orphan solute carrier SLC25A48
82 may be a choline transporter. Overexpressed SLC25A48 localizes to mitochondria in human
83 epithelial cells (**Fig. 1b**). We therefore isolated mitochondria of cells over-expressing SLC25A48
84 and measured mitochondrial uptake of radio-labelled choline (**Fig. 1c**). Mitochondria from
85 cells over-expressing SLC25A48 showed a significant increase of choline uptake compared to
86 mitochondria from control cells (**Fig. 1d**). Mitochondrial uptake of choline was time- and
87 concentration-dependent (**Fig. 1e, f**). These data establish that SLC25A48 is a newly identified,
88 high-affinity mitochondrial choline transporter. SLC25A48 transports choline at nanomolar
89 concentrations (**Fig. 1f**), and thus operates at physiological concentrations of free choline in
90 humans (7-20 μM)¹¹.

91

92 To test whether there is a causal link between altered choline levels in humans and impaired
93 mitochondrial choline transport, we investigated the aggregated impact of rare, putatively
94 damaging variants in *SLC25A48* and found significant associations with urine and plasma
95 choline levels (burden test P-values 1.4e-17 and 4.2e-06, respectively; **Supplementary Table**
96 **1**). Carriers of driver variants (Methods) showed significantly higher levels of choline
97 compared to non-carriers, which was more pronounced in urine than in plasma (**Fig. 2a**).
98 Identified driver variants mapped into different regions of *SLC25A48* (**Fig. 2b**).

99

100 Choline has been implicated in various human conditions ranging from neurological diseases
101 to metabolic traits, but there is limited evidence linking genetic defects in choline transport
102 to human disease. We therefore tested whether choline-related, putative loss-of-function
103 (pLoF) mutations in *SLC25A48* were associated with any of the human traits and diseases

104 ascertained in the UK Biobank that are related to tissues where *SLC25A48* is highly expressed
105 (Methods). Although none of the binary (**Supplementary Table 2**) or quantitative
106 (**Supplementary Table 3**) traits was significantly associated with *SLC25A48* pLoF carrier status
107 after correction for multiple testing, we note several suggestive associations with congenital,
108 musculoskeletal, neurological, and eye diseases or traits.

109

110 To investigate whether implicated variants were indeed causally related to altered choline
111 levels, we generated four mutations in the *SLC25A48* cDNA using site-directed mutagenesis
112 and over-expressed these variants in human cell lines to study their effect on protein
113 expression, localization, and function. Western blot analyses showed reduced protein
114 expression of some but not all investigated *SLC25A48* mutations compared to wild-type
115 protein (**Fig. 2c**). Interestingly, some mutations showed mis-localization from mitochondria
116 (p.R179P and p.R243*), with a significant reduction of the mitochondrial co-localization index
117 compared to wild-type *SLC25A48* (**Fig. 2d, e; Supplementary Fig. 2**), whereas other mutations
118 localized to mitochondria like wild-type transporters (p.D27G and p.R64L; **Supplementary Fig.**
119 **2**). These data show that only some of the investigated *SLC25A48* mutations result in reduced
120 protein expression and/or mis-localization.

121

122 We subsequently measured choline uptake in mitochondria to investigate which mutations
123 affect *SLC25A48* transport function. Despite differences in abundance and localization, all
124 tested *SLC25A48* mutations significantly impaired mitochondrial choline uptake (**Fig. 2f**).
125 These data establish a causal link between impaired mitochondrial choline transport via
126 *SLC25A48* and altered plasma and urine choline levels in humans. From a mechanistic
127 standpoint, our data suggest that the investigated mutations cause loss-of-function through

128 different pathogenic mechanisms, including reduced expression, mis-localization, and
129 impaired substrate turnover with normal expression level and localization.

130 To gain a better mechanistic understanding why specific mutations cause impaired
131 transport, we analyzed structural models of SLC25A48 in two conformations (**Fig. 2g,**
132 **Supplementary Fig. 3**). The SLC25A48 models were in very good agreement with experimental
133 structures of other SLC25 family members, such as the ADP/ATP carrier and mitochondrial
134 uncoupling protein (UCP) (**Supplementary Fig. 3**). Notably, residue D27 is part of a matrix-salt-
135 bridge network of conserved residues, which is a key component of the matrix gate of these
136 transporters and thus essential for transport function. This in line with the strongly impaired
137 choline transport of p.D27G despite its normal localization^{12,13}. The other mutations were also
138 localized on the matrix side of the transporter and may affect its folding and stability.

139
140 In summary, we show that the physiological function of SLC25A48 in humans is choline import
141 into mitochondria. Loss-of-function mutations in *SLC25A48* impair choline transport into
142 mitochondria, thereby causing higher levels of free choline in urine and plasma. The
143 deorphanization of SLC25A48 defines its molecular function in humans and enables future
144 well-powered studies addressing its role in health and disease.

145

146 **Figure legends**

147

148 **Fig. 1: SLC25A48 is a human mitochondrial choline transporter. (a)** Regional association plot
149 showing association of common genetic variants in the *SLC25A48* locus with choline levels in
150 urine. **(b)** Flag-tagged SLC25A48 localizes to mitochondria as shown by co-localization with the
151 mitochondrial protein COX4. Colors in merged image: SLC25A48 (turquoise), COX4 (violet),
152 and DAPI (blue). scale bar: 5 μ M. **(c, d)** Mitochondrial uptake of radio-labelled 3 H-choline in
153 cells expressing SLC25A48 compared to mock-transfected control cells (n=10). Average counts
154 per minute (CPMA). *** p<0.001. **(e)** Time course of relative choline uptake in mitochondria.
155 **(f)** Concentration-dependence of choline uptake in mitochondria from cells expressing
156 SLC25A48 compared to mock-transfected controls.

157

158 **Fig. 2: Rare damaging variants in SLC25A48 impair choline transport. (a)** Comparison of
159 inverse normal transformed choline levels in urine and plasma among carriers (N=47) and
160 non-carriers (N=5,572 for urine; N=4,666 for plasma) of putative rare damaging driver variants
161 in *SLC25A48* (P-value unpaired t-test (two-tailed): 3.8e-21 for urine and 1.3e-07 for plasma).
162 **(b)** Localization of rare, damaging driver variants with respect to their protein position in
163 SLC25A48 (Q6ZT89 corresponding to transcript ENST00000681962.1, domains based on
164 InterPro, x-axis). Symbol shape corresponds to variant consequence and the size represents
165 the positive effect size of each individual variant on urine choline levels (**Supplementary Table**
166 **1**). Individual variant association P-values with urine choline levels are shown on the y-axis.
167 Variants selected for subsequent functional analyses are labeled. **(c)** Western blot analysis of
168 wild type versus mutant flag-tagged SLC25A48. Actin was used as loading control. **(d)** Cellular
169 localization of the SLC25A48 missense mutation p.R179P compared to wild type SLC25A48.

170 Indirect immunofluorescence of SLC25A48-flag and COX4 as mitochondrial marker. Colors in
171 merged image: SLC25A48 (turquoise), COX4 (violet), and DAPI (blue). scale bar: 5 μ M. **(e)**
172 Quantification of co-localization of SLC25A48 and COX4 (Pearson correlation coefficient)
173 shows a significant reduction of mitochondrial localization of SLC25A48-R179P compared to
174 wild type (**** $p < 0.0001$; see **Supplementary Fig. 2** for other mutants). **(f)** Relative
175 mitochondrial uptake of radio-labelled ^3H -choline in cells expressing wild-type and mutant
176 SLC25A48. Transport of mutant SLC25A48 was normalized to wild-type transport. * $p < 0.05$,
177 **** $p < 0.0001$. **(g)** Position of damaging mutations in model of SLC25A48 (AlphaFold) in
178 intermembrane space (IMS)-facing conformation (helices numbered). Left: Side chains of
179 mutant residues are highlighted in pink. The protein part that would be truncated in p.R243*
180 is colored in pink. Center, right: Residues of the conserved matrix-salt-bridge network (dotted
181 line) including D27 (mutation in p.D27G) are highlighted in red and blue sticks for acidic and
182 basic residues, respectively.
183

184 **Methods**

185

186 **Molecular biology**

187 pDONR221_SLC25A48 was a gift from the RESOLUTE Consortium (Addgene plasmid # 131995;
188 <http://n2t.net/addgene:131995>; RRID:Addgene_131995). To incorporate a 5'-Mlu1- and a 3'-
189 Not1-restriction site into the SLC25A48 transcript, PCR was carried out using Pfu Ultra enzyme
190 and the following primers CGC GGG ACG CGT GCC ACC ATG GGC AGC TTC CAG CTG GA and
191 CGC GGG GCG GCC GCC TGG GGA TGT CAC TGC GTG. The resulting fragment was ligated into
192 the pcDNA6.flag vector. To generate plasmids with specific damaging variants, site-directed
193 mutagenesis was performed using the following primers: hSLC25A48.flag_D27G: CTT GTC TTC
194 hSLC25A48.flag_F64L: GCT GGC CAG TGG TAA AGA CAT GCC CTT AAA GAA GCC; GGC TTC TTT
195 AAG GGC ATG TCT TTA CCA CTG GCC AGC; hSLC25A48.flag_R179P: GCT TGC TCC CGG ATA CAG
196 TCC TGC CAG TCC C; GGG ACT GGC AGG ACT GTA TCC GGG AGC AAG C; To obtain the truncated
197 version SLC25A48.flag_R243*, a shorter transcript was derived from the
198 hSLC25A48.flag.pcDNA6 plasmid through PCR with the primers CGC GGG ACG CGT GCC ACC
199 ATG GGC AGC TTC CAG CTG GA and CGC GGG GCG GCC GCC AGA CTT CAC CAC GTC CAT which
200 then was subcloned into pcDNA6.flag vector as described before.

201

202 **Cell Culture**

203 HEK293T and HeLa cell lines were obtained from the American Type Culture Collection. Both
204 cell lines were cultured as adherent monolayers in Dulbecco's Modified Eagle Medium
205 (DMEM, Gibco), supplemented with 10% heat-inactivated fetal bovine serum (FBS, Biochrom)
206 and Penicillin-Streptomycin (Sigma Aldrich P8781) in a humidified incubator with 5% CO₂ at a
207 temperature of 36.5°C. Cells were routinely passaged every 3–4 days using 0.05% trypsin-

208 EDTA (Invitrogen) for detachment. For transfection, HEK293T cells were transfected with
209 either 10 µg of plasmid per 55 cm² dish or 100 µg of plasmid per 500 cm² plates using the
210 calcium phosphate transfection method. HeLa cells were transfected using FuGENE HD
211 transfection reagent according to the manufacturer's instructions (Promega E2311).

212

213 **Protein isolation, gel electrophoresis, and Western blot**

214 Cells were harvested 48 hours post transfection, and protein isolation and processing were
215 conducted following established procedures as described previously¹⁴. Briefly, cell samples
216 were lysed in a cold IP buffer (1% Triton X-100, 20 mM Tris-HCl pH 7.5, 50 mM NaCl, 50 mM
217 NaF, 15 mM Na₄P₂O₇, and 0.1 mM EDTA pH 8) supplemented with 2 mM Na₃VO₄ and complete
218 protease inhibitor cocktail tablets (Roche 11697498001). The lysates were then subjected to
219 centrifugation at 4°C for 15 minutes at 10,000 g. Supernatants were prepared for further
220 analysis by denaturation for 30 minutes at 42°C with 2x Laemmli buffer.

221 The denatured protein samples were separated using SDS-PAGE, employing precast
222 Mini-PROTEAN TGX 4-15% gels (BioRad 4561086). The separated proteins were then
223 transferred onto PVDF membranes via a wet blot system for 1 hour at 100 V (BioRad).
224 Membranes were blocked with 5% BSA and subsequently incubated with primary antibodies
225 anti-flag (1:3000; Sigma Aldrich F3165) and anti-β-actin (1:5000; Sigma Aldrich A1978)
226 overnight at 4°C. For detection secondary antibodies (anti-rabbit (GE Healthcare NA934V) and
227 anti-mouse (Dako P0447), were used at a dilution of 1:10,000). Chemiluminescence signals
228 were acquired using the Intas ChemoCam system (Intas Science Imaging) within the dynamic
229 range of the charge-coupled device sensor, ensuring that none of the analyzed bands were
230 saturated. The Western blot in Fig. 2c is representative of three experiments with similar
231 results.

232

233 **Immunofluorescence**

234 300,000 HeLa cells were seeded in μ dish 35mm dishes (ibidi, 81156) and transfected the
235 following day with 2.5 μ g of plasmid in 7.8 μ l of FuGENE HD transfection reagent (Promega,
236 E2311) and 117.2 μ l of water. Two days after transfection, cells were fixed with 3.2 %
237 paraformaldehyde (PFA) for 7 minutes 30 seconds and then permeabilized with a 0.05%
238 Triton-X solution in PBS for 15 minutes. A blocking step was carried out using a mixture of 5%
239 horse serum and 1% BSA in PBS (IF blocking buffer) for 1 hour at RT.

240 The cells were then incubated overnight with primary antibodies in IF blocking buffer,
241 including anti-flag (Sigma Aldrich F3165, 1:1000) and anti-COX4 (Cell Signaling 4850, 1:200).
242 The following day, the samples were incubated with secondary antibodies for 90 minutes
243 (Hoechst 33342 (Thermo Fisher Scientific, H1399, 1:10000), Alexa Fluor 647 goat anti-rabbit
244 (Invitrogen, A21245, 1:1000), and anti-mouse Alexa Fluor 488 (Molecular Probes, A-11029)).
245 washed, and mounted for microscopy (Dako Glycergel, Agilent). IF-Imaging was performed on
246 a on a LSM980 MP AiryScan 2 equipped with Plan-Apochromat 63x 1.4 oil (Zeiss) within the
247 dynamic range of the detector (pixel size 59 nm x 59 nm). A quantitative colocalization analysis
248 of Flag-tagged SLC25A48 (Alexa Fluor 488) and COX4 (Alexa Fluor 647) was performed with
249 the Colocalization plugin in the Zeiss ZEN blue 3.4 software. 55 to 86 ROIs per group
250 comprising whole cells without nucleus originating from three independent transfections
251 were manually determined. Costes optimal threshold was applied and pixel-based
252 colocalization between two channels was measured to calculate Pearson's correlation
253 coefficient per ROI.

254

255

256 **Mitochondrial isolation**

257 HEK293T cells were seeded in a 1:12 dilution in 500 cm² plates and transfection was
258 performed the following day. Two days after transfection, cells were harvested to obtain crude
259 mitochondrial pellets, following the protocol described in¹⁵. The mitochondrial pellets were
260 resuspended in a mitochondrial uptake buffer, which was composed of KCl (120 mM), sucrose
261 (25 mM), HEPES (10 mM), EGTA (1 mM), KH₂PO₄ (1 mM), MgCl₂ (5 mM), glutamate (15 mM),
262 and malate (7.5 mM), adjusted to a pH 7.2⁶.

263

264 **³H choline Transport studies**

265 A total of 25 µg of crude mitochondria was suspended in 50 µl of mitochondrial uptake buffer
266 at room temperature. Subsequently, 50 µl of 2x choline buffer (mitochondrial uptake buffer
267 supplemented with 20 µM choline chloride (Merck C7017-5G) (cold choline)), and 10 nM
268 Choline Chloride, [Methyl-³H]-, 1 mCi (revvity, NET109001MC) (hot choline)), resulting in a
269 final concentration of 10 µM cold choline and 5 nM hot choline. The mixture was incubated
270 at room temperature for 5 minutes to facilitate radiolabeled transport.

271 Upon completion of the incubation, 1 ml of ice-cold mitochondria washing buffer
272 (mitochondrial uptake buffer containing an additional 20 µM choline chloride) was added, and
273 the samples were promptly placed on ice. Following this, centrifugation was carried out at
274 10,000 g for 5 minutes at 4°C to remove the radiolabeled choline. The resulting pellet was
275 subjected to an additional wash with 300 µl of mitochondria washing buffer through
276 centrifugation at 10,000 g for 5 minutes at 4°C. The final mitochondrial pellet was
277 resuspended in 4 ml of Ultima Gold scintillation cocktail (revvity 6013329), and the ³H-choline
278 content was quantified using liquid scintillation counting.

279 For time-course experiments, the incubation duration for radiolabeled transport was varied:
280 30 seconds, 1 minute, 2 minutes, 3 minutes, 5 minutes, 15 minutes, and 30 minutes. For
281 concentration dependence experiments, the choline buffer exclusively contained hot choline
282 (no cold choline) at four different concentrations: 0.05 nM, 0.5 nM, 5 nM, and 50 nM. For
283 time- or concentration-dependent choline uptake experiments, data were normalized to the
284 30 s timepoint or the 0.5 nM measurement from control samples respectively (Fig. 1e, f). For
285 the quantification of relative choline transport (Fig. 2f), the transport activity of mock-
286 transfected mitochondria was subtracted from the transport activity observed in
287 mitochondria over-expressing wild type and mutant SLC25A48, and normalized to the
288 respective wild type transport activity.

289

290 **Statistics**

291 GraphPad Prism® 9.5.1 software was used to graph, analyze and present the obtained data.
292 All results are expressed as mean \pm SEM. All experiments were independently performed at
293 least three times and two-tailed Mann-Whitney test was used to calculate p values. A p-
294 value < 0.05 was considered significant.

295

296 **Study population**

297 Genetic associations with choline levels were evaluated in the German Chronic Kidney Disease
298 (GCKD) study, an ongoing prospective cohort study of 5,217 participants with chronic kidney
299 disease stages G3; A1-3 or G1-2; A3 at inclusion that has been described in detail before^{16,17}.
300 Plasma and urine samples originate from the study's baseline visit, where biosamples were
301 collected, processed, and shipped frozen to a central biobank for storage at -80 degrees
302 Celsius¹⁸. The GCKD study was registered in the national registry for clinical studies (DRKS

303 00003971) and approved by local ethics committees of the participating institutions¹⁶. All
304 participants provided written informed consent.

305
306 **Measurement of choline levels**

307 Choline was measured as part of the non-targeted mass spectrometry-based Metabolon HD4
308 Global Discovery panel at Metabolon, Inc. Generation and processing of metabolomics data
309 from stored plasma and spot urine samples of the GCKD study has been described previously².
310 Briefly, metabolites were identified by automated comparison of the ion features in the
311 experimental sample to a reference library of chemical standards. Peak quantification was
312 based on the area under the curve, followed by normalization to account for inter-day
313 instrument variation. After quality control, choline levels in urine were normalized for inter-
314 individual dilution using the probabilistic quotient method¹⁹. Prior to gene-based aggregation
315 testing, choline levels were inverse normal transformed.

316
317 **Whole Exome Sequencing (WES)**

318 The *SLC25A48* gene was investigated using WES data of GCKD participants, which has been
319 described previously²⁰. Briefly, extracted genomic DNA underwent paired-end 100-bp WES at
320 Human Longevity Inc, using the IDT xGen v1 capture kit on the Illumina NovaSeq 6000
321 platform. The average coverage of the consensus coding sequence (CCDS) release 22 was 141-
322 fold read depth. Exomes were processed in a custom-built cloud compute platform using the
323 Illumina DRAGEN Bio-IT Platform Germline Pipeline v3.0.7 at Astra Zeneca's Centre for
324 Genomics Research, including alignment to the GRCh38 reference genome and variant
325 calling²¹.

326 Sample quality control comprised removal of duplicates, samples with withdrawn
327 consent, mismatch of genetic and reported sex, gonosomal aneuploidies, estimated
328 VerifyBamID contamination level >4%, <94.5% of CCDS bases covered with ≥ 10 -fold coverage,
329 highly related samples (kinship >0.884 by KING --kinship v2.2.3)²¹, and missing sample call rate
330 >0.03. Only samples with available high-quality DNA microarray genotype data and without
331 outlying values (>8 SD) along any of the first 10 genetic principal components from a PCA were
332 retained, for a final sample size of 4,779 samples.

333 Variant quality control comprised exclusion for coverage of <10x, genotype quality
334 score (GQ) <30, mapping quality score (MQ) <40, quality score (QUAL) <30, read position rank
335 sum score (RPRS) <-2, mapping quality rank sum score (MQRS) <-8, heterozygous variants with
336 a one-sided binomial exact test P-value for Hardy-Weinberg equilibrium of <1e-6 or genotype
337 called based on an alternative allele read ratio <0.2 or >0.8, single nucleotide variants with a
338 Fisher's strand bias score (FS) >60 and insertions and deletions (indel) with a FS >200, variants
339 that did not pass the DRAGEN calling algorithm filters, and variants with a missing call rate
340 >10% among all remaining samples.

341

342 **Variant annotation and rare variant aggregation (burden) testing**

343 Called variants were annotated using Variant Effect Predictor (VEP)²² version 109 with
344 standard settings. Predicted deleteriousness of variants was added via REVEL²³ (version 2020-
345 5) and CADD²⁴ (version 3.0) VEP plugins and via dbNSFP version 4.1a for additional prediction
346 scores²⁵. The LoFtee VEP plugin²⁶ (version 2020-8) was used to downgrade loss-of-function
347 variants. Only variants in transcript ENST00000681962.1, annotated as the MANE Select and
348 Ensembl Canonical transcript for *SLC25A48* by VEP, were considered.

349 The burden test is appropriate when all variants are assumed to affect the trait in the
350 same direction, as is the case for pLoF variants²⁷. Qualifying variants in *SLC25A48* for
351 aggregation in burden tests were selected based on variant frequency and VEP annotations.
352 Two complementary masks of selected variants were evaluated: while both masks only
353 assessed rare variants with MAF of <1% in the MANE Select transcript ENST00000681962.1,
354 they differed in the selection of predicted variant effect. The “LoF_mis” mask contained all
355 variants that were predicted to be either high-confidence loss-of-function variants or
356 missense variants with a MetaSVM score >0 or in-frame non-synonymous variants with a
357 fathmm-XF-coding score >0.5, whereas the “HI_mis” mask contained all variants that were
358 predicted either to have a high-impact consequence defined by VEP (transcript ablation, splice
359 acceptor variant, splice donor variant, stop gained, frameshift variant, stop lost, start lost, and
360 transcript amplification) or to be missense variants with either a REVEL score >0.5, a CADD
361 PHRED score >20, or a M-CAP score >0.025. Burden tests were carried out as implemented in
362 the seqMeta R-package version 1.6.7²⁸, adjusting for age, sex, ln(eGFR), the first three genetic
363 principal components as well as serum albumin for plasma choline and ln(UACR) for urine
364 choline, respectively. Genotypes were coded as number of copies of the rare allele (0, 1, 2).
365 Statistical significance was defined as $p < 0.05$. Single-variant association tests between each
366 selected variant and choline levels were performed under additive modeling, adjusting for the
367 same covariates. To prioritize selected rare putatively damaging variants according to their
368 contribution to the gene signal, we used a previously described forward selection procedure²⁹:
369 variants v were ranked by the magnitude of the difference $\Delta_v = P_v - P$, where P_v corresponds to
370 the p-value of the burden test aggregating all variants except for the variant v , and P to the
371 total P-value of the burden test including all selected variants. Variants with the greatest Δ_v
372 providing the lowest p-value when aggregated are referred to as “driver variants”. Lower

373 association p-values were observed with the “HI_mis” mask as compared to the “LoF_mis”
374 mask, suggesting that the former better captures the genetic architecture of *SLC25A48* with
375 respect to choline levels. Therefore, results are shown for the “HI_mis” mask.

376
377 **Associations with human traits and diseases**

378
379 **Colocalization analysis**

380 We performed colocalization analysis to investigate whether genetic variants associated with
381 choline levels were also associated with gene expression levels (i.e., if these variants act as
382 expression quantitative trait loci, eQTLs). Summary statistics for eQTLs were obtained from
383 the Genotype-Tissue Expression Project (GTEx, V8)³⁰. We focused on *SLC25A48* expression in
384 tissues where *SLC25A48* was tissue-enhanced according to the Human Protein Atlas³¹: brain,
385 kidney, and skeletal muscle. For colocalization we used the “coloc” R package and applied the
386 enumeration approach implemented in the “coloc.abf” function³². This approach tests
387 whether two traits share the same causal variant in a region by estimating posterior
388 probabilities for five hypotheses: both traits have no causal variant in a region (hypothesis
389 H0), either the first or the second trait has a causal variant (H1 and H2, respectively), both
390 traits have causal variants but they are distinct (H3), and both traits share a common causal
391 variant (H4). Posterior probabilities are assigned to each hypothesis and their sum is equal to
392 1. Two traits show evidence for genetic colocalization when hypothesis H4 obtains the highest
393 probability (0.5 or higher).

394
395
396

397 **Rare variant collapsing analysis**

398 We performed genome-wide association analysis of rare variants in *SLC25A48* with binary
399 traits (clinical diagnoses based on ICD-10 codes) and quantitative traits in the UK Biobank,
400 which comprises up to 500,000 individuals with WES and comprehensive phenotypic data³³
401 (UK Biobank application ID 64806). We excluded strongly related individuals (for whom ten or
402 more third-degree relatives were identified) and individuals not included in the kinship
403 inference process. Participants of all ancestries were included into analysis. To adjust for
404 population stratification, we included the first 10 principal components based on genotype
405 array data (UKB Data-Field 22009) when performing all downstream regression analyses for
406 both binary and quantitative traits. In addition to principal components, we included sex, age
407 at recruitment, and interaction between sex and age (sex*age) as covariates.

408 After individual-level filtering, a total of 468,292 individuals were available for
409 association analyses. Both masks were tested: “LoF_mis” (94 variants) and “HI_mis” (191
410 variants)²⁰. All variants in each mask passed the “90pct10dp” quality filter, defined as a read
411 depth of at least 10 in at least 90% of all genotypes for a given variant independent of variant
412 allele zygosity. Carriers and non-carriers of variants in each mask were compared using the
413 collapsing approach, in which carriers are defined as individuals with either heterozygous or
414 alternative homozygous genotype for at least one of the variants in the mask. The remaining
415 individuals were defined as non-carriers. All analyses were performed on the UK Biobank
416 Research Analysis Platform.

417

418 **Analysis of binary traits and diseases**

419 Traits and diseases were defined based on ICD-10 codes (International Classification of
420 Diseases, 10th Revision). We queried all distinct diagnosis codes from the UK Biobank

421 database for each participant across all hospital inpatient records in either the primary or
422 secondary position (UK Biobank Data-Field 41270). Next, we grouped ICD-10 codes using
423 phecode system³⁴. The phecode system maps related ICD-10 codes to a larger group of codes
424 known as “phecode”. In total, there are approximately 1,500 phecodes. Each phecode is
425 assigned to a clinically meaningful category (e.g., neurological diseases, musculoskeletal
426 diseases) to facilitate interpretation. We analyzed 658 phecodes belonging to the following
427 categories: circulatory system, congenital anomalies, digestive, endocrine/metabolic,
428 genitourinary, mental disorders, musculoskeletal, neurological, pregnancy complications, and
429 retinal traits from sense organs. For each phecode, we defined case-control status of
430 participants based on the presence or absence of the respective phecode. Since we focused
431 on rare variants, we applied Firth’s logistic regression for association testing (mean bias-
432 reducing adjusted scores approach) as implemented in the “brglm2” R package³⁵. Firth’s
433 regression provides bias-reduction in case of rare events and also allows for inclusion of
434 covariates. We report 83 phecodes from both masks (73 unique phecodes) with nominally
435 significant associations (P-value <0.05) in **Supplementary Table 2**.

436

437 **Analysis of quantitative traits**

438 Among quantitative traits available in the UK Biobank, we selected a subset of 1,143 physical
439 measures, blood assays, and imaging traits that belonged to the following categories: Chapter
440 V Mental and behavioural disorders, Chapter VI Diseases of the nervous system, Chapter VII
441 Diseases of the eye and adnexa, Chapter IX Diseases of the circulatory system, Chapter XI
442 Diseases of the digestive system, Chapter XIII Diseases of the musculoskeletal system and
443 connective tissue, Chapter XIV Diseases of the genitourinary system²¹, as well as all available
444 blood biochemistry measurements from all chapters. Values of these traits were inverse-

445 normal transformed prior to analyses. We applied linear regression for association testing
446 between quantitative traits and collapsed variants adjusting for covariates as mentioned
447 above. We report 106 quantitative traits from both masks (103 unique traits) with nominally
448 significant associations (P-value <0.05) in **Supplementary Table 3**.

449 450 **Structural model generation and analysis**

451 The SLC25A48 AlphaFold³⁶ model was retrieved from the AlphaFold Protein Structure
452 Database³⁷ hosted by EMBL-EBI (<https://alphafold.ebi.ac.uk>, accession code Q6ZT89). To
453 identify potential homologous proteins with experimental structures available, a sequence-
454 based BLAST³⁸ search of the Protein Data Bank as well as a structural homology based search
455 using the DALI Server³⁹ were performed. Structures of other SLC25 family members with
456 accession codes 1ock (ADP/ATP carrier from bovine⁴⁰), 2lck (UCP2 from mouse⁴¹), 4c9g
457 (ADP/ATP carrier 2 from yeast⁴²), 4c9j (ADP/ATP carrier 3 from yeast⁴²), 6gci (ADP/ATP carrier
458 from *Thermothelomyces thermophilus*⁴³), 8g8w (UCP1 from human, GTP bound¹²) and 8hbv
459 (UCP1 from human, nucleotide-free state⁴⁴) were obtained from the Protein Data Bank.
460 Structures and model were superimposed using Coot⁴⁵. As the SLC25A48 AlphaFold model is
461 in the intermembrane space open conformation, Swiss-Model⁴⁶ was used to model the matrix
462 open conformation using the structure of ADP/ATP carrier from *T. thermophilus*⁴³ in matrix
463 open conformation as template. Figures were prepared using the PyMOL Molecular Graphics
464 System, Schrödinger, LLC.

465

466 **Acknowledgements**

467 The cDNA for SLC25A48 was kindly provided by the RESOLUTE consortium (<https://re->
468 [solute.eu](https://re-solute.eu)). The authors acknowledge Simone Diederichsen and Andreas Ungi for expert
469 technical assistance and graphic support. We would like to thank the Lighthouse Core Facility
470 for assistance with microscopy and cell sorting. The work of N.S., C.H., B.N., A.K. and M.K. was
471 funded by German Research Foundation (DFG) project ID 431984000 (SFB 1453). N.S. was
472 supported by DFG KO 3598/4-2 (to A.K.). M.K. was supported by German Research Foundation
473 (DFG) project ID 239283807 (TRR 152). Germany's Excellence Strategy (CIBSS, EXC-2189,
474 project ID 390939984) supported the work of C.H., A.K., and M.K.. S.P. was funded by H2020
475 MSCA-ITN-2019 ID:860977 (TrainCKDis). The work of P.S. was supported by DFG Project-ID
476 523737608 (SCHL 2292/2-1). Genotyping and urine metabolomics in the GCKD study were
477 supported by Bayer Pharma. Plasma metabolomics has received funding from the Innovative
478 Medicines Initiative 2 Joint Undertaking (JU) under grant agreement no. 115974. The JU
479 receives support from the European Union's Horizon 2020 research and innovation program
480 and the EFPIA and the JDRF. Any dissemination of results reflects only the authors' view; the
481 JU is not responsible for any use that may be made of the information it contains. The GCKD
482 study was and is supported by the BMBF (FKZ 01ER 0804, 01ER 0818, 01ER 0819, 01ER 0820
483 and 01ER 0821) and the KfH Foundation for Preventive Medicine. Unregistered grants to
484 support the study were provided by corporate sponsors (listed at <https://gckd.org>). We are
485 grateful for the willingness of the patients to participate in the GCKD study. The effort of the
486 study personnel of the various regional centers is highly appreciated. We thank the large
487 number of nephrologists who provide routine care for the patients and collaborate with the
488 GCKD study.

489

490 References

491

- 492 1. Meixner, E. *et al.* A substrate-based ontology for human solute carriers. *Mol Syst Biol*
493 **16**, e9652 (2020).
- 494 2. Schlosser, P. *et al.* Genetic studies of paired metabolomes reveal enzymatic and
495 transport processes at the interface of plasma and urine. *Nat Genet* **55**, 995-1008
496 (2023).
- 497 3. Suhre, K. *et al.* Human metabolic individuality in biomedical and pharmaceutical
498 research. *Nature* **477**, 54-60 (2011).
- 499 4. Ueland, P.M. Choline and betaine in health and disease. *J Inherit Metab Dis* **34**, 3-15
500 (2011).
- 501 5. Apparsundaram, S., Ferguson, S.M., George, A.L., Jr. & Blakely, R.D. Molecular cloning
502 of a human, hemicholinium-3-sensitive choline transporter. *Biochem Biophys Res*
503 *Commun* **276**, 862-7 (2000).
- 504 6. Bennett, J.A. *et al.* The choline transporter Slc44a2 controls platelet activation and
505 thrombosis by regulating mitochondrial function. *Nat Commun* **11**, 3479 (2020).
- 506 7. Cater, R.J. *et al.* Structural and molecular basis of choline uptake into the brain by
507 FLVCR2. *bioRxiv* (2023).
- 508 8. Kenny, T.C. *et al.* Integrative genetic analysis identifies FLVCR1 as a plasma-membrane
509 choline transporter in mammals. *Cell Metab* **35**, 1057-1071 e12 (2023).
- 510 9. Michel, V. & Bakovic, M. The solute carrier 44A1 is a mitochondrial protein and
511 mediates choline transport. *FASEB J* **23**, 2749-58 (2009).
- 512 10. Traiffort, E., O'Regan, S. & Ruat, M. The choline transporter-like family SLC44:
513 properties and roles in human diseases. *Mol Aspects Med* **34**, 646-54 (2013).
- 514 11. Garcia, E. *et al.* Quantification of choline in serum and plasma using a clinical nuclear
515 magnetic resonance analyzer. *Clin Chim Acta* **524**, 106-112 (2022).
- 516 12. Jones, S.A. *et al.* Structural basis of purine nucleotide inhibition of human uncoupling
517 protein 1. *Sci Adv* **9**, eadh4251 (2023).
- 518 13. Ruprecht, J.J. & Kunji, E.R.S. The SLC25 Mitochondrial Carrier Family: Structure and
519 Mechanism. *Trends Biochem Sci* **45**, 244-258 (2020).
- 520 14. Hofherr, A. *et al.* The mitochondrial transporter SLC25A25 links ciliary TRPP2
521 signaling and cellular metabolism. *PLoS Biol* **16**, e2005651 (2018).
- 522 15. Wieckowski, M.R., Giorgi, C., Lebedzinska, M., Duszynski, J. & Pinton, P. Isolation of
523 mitochondria-associated membranes and mitochondria from animal tissues and
524 cells. *Nat Protoc* **4**, 1582-90 (2009).
- 525 16. Eckardt, K.U. *et al.* The German Chronic Kidney Disease (GCKD) study: design and
526 methods. *Nephrol Dial Transplant* **27**, 1454-60 (2012).
- 527 17. Titze, S. *et al.* Disease burden and risk profile in referred patients with moderate
528 chronic kidney disease: composition of the German Chronic Kidney Disease (GCKD)
529 cohort. *Nephrol Dial Transplant* **30**, 441-51 (2015).
- 530 18. Prokosch, H.U. *et al.* Designing and implementing a biobanking IT framework for
531 multiple research scenarios. *Stud Health Technol Inform* **180**, 559-63 (2012).
- 532 19. Dieterle, F., Ross, A., Schlotterbeck, G. & Senn, H. Probabilistic quotient normalization
533 as robust method to account for dilution of complex biological mixtures. Application
534 in 1H NMR metabolomics. *Anal Chem* **78**, 4281-90 (2006).

- 535 20. Pfau, A. *et al.* SLC26A1 is a major determinant of sulfate homeostasis in humans. *J*
536 *Clin Invest* **133**(2023).
- 537 21. Wang, Q. *et al.* Rare variant contribution to human disease in 281,104 UK Biobank
538 exomes. *Nature* **597**, 527-532 (2021).
- 539 22. McLaren, W. *et al.* The Ensembl Variant Effect Predictor. *Genome Biol* **17**, 122 (2016).
- 540 23. Ioannidis, N.M. *et al.* REVEL: An Ensemble Method for Predicting the Pathogenicity of
541 Rare Missense Variants. *Am J Hum Genet* **99**, 877-885 (2016).
- 542 24. Rentzsch, P., Witten, D., Cooper, G.M., Shendure, J. & Kircher, M. CADD: predicting
543 the deleteriousness of variants throughout the human genome. *Nucleic Acids Res* **47**,
544 D886-D894 (2019).
- 545 25. Liu, X., Li, C., Mou, C., Dong, Y. & Tu, Y. dbNSFP v4: a comprehensive database of
546 transcript-specific functional predictions and annotations for human nonsynonymous
547 and splice-site SNVs. *Genome Med* **12**, 103 (2020).
- 548 26. Karczewski, K.J. *et al.* The mutational constraint spectrum quantified from variation in
549 141,456 humans. *Nature* **581**, 434-443 (2020).
- 550 27. Lee, S., Abecasis, G.R., Boehnke, M. & Lin, X. Rare-variant association analysis: study
551 designs and statistical tests. *Am J Hum Genet* **95**, 5-23 (2014).
- 552 28. Voorman, A., Brody, J., Chen, H., Lumley, T. & Davis, B. . seqMeta: Meta-Analysis of
553 Region-Based Tests of Rare DNA Variants. (2017).
- 554 29. Bomba, L. *et al.* Whole-exome sequencing identifies rare genetic variants associated
555 with human plasma metabolites. *Am J Hum Genet* **109**, 1038-1054 (2022).
- 556 30. Consortium, G.T. The GTEx Consortium atlas of genetic regulatory effects across
557 human tissues. *Science* **369**, 1318-1330 (2020).
- 558 31. Uhlen, M. *et al.* Proteomics. Tissue-based map of the human proteome. *Science* **347**,
559 1260419 (2015).
- 560 32. Giambartolomei, C. *et al.* Bayesian test for colocalisation between pairs of genetic
561 association studies using summary statistics. *PLoS Genet* **10**, e1004383 (2014).
- 562 33. Bycroft, C. *et al.* The UK Biobank resource with deep phenotyping and genomic data.
563 *Nature* **562**, 203-209 (2018).
- 564 34. Wu, P. *et al.* Mapping ICD-10 and ICD-10-CM Codes to Phecodes: Workflow
565 Development and Initial Evaluation. *JMIR Med Inform* **7**, e14325 (2019).
- 566 35. Kosmidis, I., Kenne Pagui, E.C. & Sartori, N. Mean and median bias reduction in
567 generalized linear models. . *Stat Comput* 43–59 (2020).
- 568 36. Jumper, J. *et al.* Highly accurate protein structure prediction with AlphaFold. *Nature*
569 **596**, 583-589 (2021).
- 570 37. Varadi, M. *et al.* AlphaFold Protein Structure Database: massively expanding the
571 structural coverage of protein-sequence space with high-accuracy models. *Nucleic*
572 *Acids Res* **50**, D439-D444 (2022).
- 573 38. Altschul, S.F., Gish, W., Miller, W., Myers, E.W. & Lipman, D.J. Basic local alignment
574 search tool. *J Mol Biol* **215**, 403-10 (1990).
- 575 39. Holm, L., Laiho, A., Toronen, P. & Salgado, M. DALI shines a light on remote
576 homologs: One hundred discoveries. *Protein Sci* **32**, e4519 (2023).
- 577 40. Pebay-Peyroula, E. *et al.* Structure of mitochondrial ADP/ATP carrier in complex with
578 carboxyatractyloside. *Nature* **426**, 39-44 (2003).
- 579 41. Berardi, M.J., Shih, W.M., Harrison, S.C. & Chou, J.J. Mitochondrial uncoupling protein
580 2 structure determined by NMR molecular fragment searching. *Nature* **476**, 109-13
581 (2011).

- 582 42. Ruprecht, J.J. *et al.* Structures of yeast mitochondrial ADP/ATP carriers support a
583 domain-based alternating-access transport mechanism. *Proc Natl Acad Sci U S A* **111**,
584 E426-34 (2014).
- 585 43. Ruprecht, J.J. *et al.* The Molecular Mechanism of Transport by the Mitochondrial
586 ADP/ATP Carrier. *Cell* **176**, 435-447 e15 (2019).
- 587 44. Kang, Y. & Chen, L. Structural basis for the binding of DNP and purine nucleotides
588 onto UCP1. *Nature* **620**, 226-231 (2023).
- 589 45. Emsley, P., Lohkamp, B., Scott, W.G. & Cowtan, K. Features and development of Coot.
590 *Acta Crystallogr D Biol Crystallogr* **66**, 486-501 (2010).
- 591 46. Waterhouse, A. *et al.* SWISS-MODEL: homology modelling of protein structures and
592 complexes. *Nucleic Acids Res* **46**, W296-W303 (2018).
593

Figure 1




Figure 2

